Alopecia Areata Research Study
We welcome you to take part in a research study exploring the financial burden of living with alopecia areata in adults.
OLUMIANT® Receives Health Canada Approval, Becoming the Second Approved Treatment for Severe Alopecia Areata in Canada
Eli Lilly Canada Inc. announced today that OLUMIANT (baricitinib) received regulatory approval for its severe alopecia areata indication via Notice of Compliance (NOC) from Health Canada.
LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada
This press release was posted on Pfizer's website on December 4, 2023. A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults